Company Overview and News

2
Abeona Therapeutics nomme João Siffert, M.D., comme Responsable recherche et développement et Directeur médical

11h globenewswire
NEW YORK et CLEVELAND, 18 oct. 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), société biopharmaceutique de stade clinique de premier plan spécialisée dans le développement de nouvelles thérapies cellulaires et géniques pour les maladies génétiques rares menaçant le pronostic vital, a annoncé aujourd’hui la nomination de João Siffert, M.D., en tant que Responsable recherche et développement et Directeur médical.
ABEO ABEOW AVNR

2
Abeona Therapeutics ernennt Dr. João Siffert zum Leiter der Forschungs- und Entwicklungsabteilung sowie zum Chief Medical Officer

11h globenewswire
NEW YORK und CLEVELAND (USA), Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes in der klinischen Erprobung tätiges Biopharma unternehmen, das sich auf die Entwicklung von neuartigen Zell- und Gentherapien für lebensbedrohliche, seltene Erbkrankheiten spezialisiert hat, hat heute die Ernennung von Dr. João Siffert zum Head of Research and Development und Chief Medical Officer bekanntgegeben.
ABEO ABEOW AVNR

11
ABEO / Abeona Therapeutics Inc. 8-K/A (Current Report)

2018-10-10 sec.gov - 10
UNITED STATES SECURITIES AND EXCHANGE COMMI
ABEO

16
ABEO / Abeona Therapeutics Inc. 8-K (Current Report)

2018-10-05 sec.gov - 15
UNITED STATES
ABEO

4
Amicus Therapeutics Buys Celenex for $100 Million up Front

2018-09-20 biospace - 2
Amicus Therapeutics, headquartered in Cranbury, New Jersey, inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex. The programs were developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and The Ohio State University. Celenex was a spinout of Nationwide Children’s Hospital.
FOLD ABEO ABEOW BMRN

5
Karyopharm Therapeutics: Can The Rally Continue?

2018-09-17 seekingalpha - 3
The stock of Karyopharm Therapeutics has advanced some 65% over the past year as its main drug candidate has advanced.
ALXN KPTI ABEO ABEOW

1
Abeona Therapeutics gibt Genehmigung für den Beginn einer klinischen Phase-I/II-Gentherapie-Studie für Patienten mit MPS IIIB in Spanien bekannt

2018-09-13 globenewswire
NEW YORK und CLEVELAND, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes, in der klinischen Erprobung tätiges Biopharmazieunternehmen, das sich auf die Entwicklung von neuartigen Zell- und Gentherapien für lebensbedrohliche, seltene Erbkrankheiten spezialisiert hat, gab heute bekannt, dass es die Genehmigung erhalten hat, in Spanien eine klinische Phase-I/II-Studie zu seinem Gentherapieprodukt ABO-101 (AAV-NAGLU) bei Patienten mit MPS IIIB (Sanfilippo-Syndrom Typ B) durchzuführen.
ABEO ABEOW

1
Abeona Therapeutics annonce l'autorisation de commencer l'étude clinique de phase 1/2 sur la thérapie génique pour les patients atteints de MPS IIIB en Espagne

2018-09-13 globenewswire
NEW YORK et CLEVELAND, 13 sept. 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), une société biopharmaceutique de premier plan axée sur le développement de nouvelles thérapies géniques et cellulaires pour les maladies génétiques rares potentiellement mortelles, a annoncé aujourd'hui l'autorisation de procéder à un essai clinique de phase 1/2 en Espagne pour le produit de thérapie génique ABO-101 (AAV-NAGLU) pour les patients atteints de MPS IIIB (syndrome de Sanfilippo de type B).
ABEO ABEOW

1
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain

2018-09-12 globenewswire
NEW YORK and CLEVELAND, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced authorization to move forward with a Phase 1/2 clinical trial in Spain for the Company’s gene therapy product ABO-101 (AAV-NAGLU) for patients with MPS IIIB (Sanfilippo syndrome type B).
ABEO ABEOW

2
Audentes Therapeutics started at sell with $20 stock price target at B. Riley FBR

2018-09-07 marketwatch - 1
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on ...[...]
BOLD AGFS AGFSW ABEO SND ABEOW

1
Abeona Announces Participation at Upcoming Conferences

2018-09-04 globenewswire
NEW YORK and CLEVELAND, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that management will participate in two investor conferences this September. To access the events that are accessible via live webcasts, please visit the investor section of Abeona’s website, www.
ABEO ABEOW

2
Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors

2018-09-04 globenewswire
-- Current Chief Executive Officer of Abeona Therapeutics, Inc. and former Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc.; Brings Wealth of Leadership and Global Strategic Experience --
ALXN KPTI ABEO ABEOW

3
ABEO / Abeona Therapeutics Inc. FORM 8-K (Current Report)

2018-08-20 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ABEO

1
ABEO / Abeona Therapeutics Inc. PROSPECTUS SUPPLEMENT (Prospectus)

2018-08-17 sec.gov
tv500572-424b5 - none - 7.6723605s TABLE OF CONTENTS
ABEO

ABEO: Abeona Therapeutics Analysis and Research Report

2018-05-14 - Asif

OVERVIEW Abeona Therapeutics Inc. is a Delaware corporation. Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. The company's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona Therapeutics is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition Abeona Therapeutics is developing a proprietary vector platform, ...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00289Y107